High GLYPICAN-3 expression Characterizes a Biologically Distinct subset of ovarian clear cell carcinomas in Canadian patients: An Opportunity for targeted Therapy.
View abstract on PubMed here.
Katharina Wiedemeyer, Martin Köbela, Holly Koelkebeck, Zhan Xiao, Kapil Vashisht
Department of Pathology and Laboratory Medicine, University of Calgary, and Alberta Public Laboratories, Calgary, Alberta, Canada and AstraZeneca, Gaithersburg, USA.
Highlights
•The oncofetal protein Glypican-3 is overexpressed in a subset of ovarian clear cell carcinomas.
•The membranous expression of Glypican-3 in ovarian clear cell carcinoma makes it an interesting immunotherapy target.
•The combination of ARID1A loss with Glypican-3 overexpression may identify a subgroup with particularly short survival.